- Home
- ECVT vs LTGO Comparison
ECVT vs LTGO Comparison
Compare ECVT & LTGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ECVT | LTGO |
|---|---|---|
| Founded | 1935 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2017 | 2026 |
Fundamental Metrics
Financial Performance| Metric | ECVT | LTGO |
|---|---|---|
| Price | $10.43 | $22.59 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $14.00 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 203.4K |
| Earning Date | 05-05-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $723,515,000.00 | N/A |
| Revenue This Year | $29.07 | N/A |
| Revenue Next Year | $6.71 | N/A |
| P/E Ratio | $96.73 | ★ N/A |
| Revenue Growth | ★ 2.70 | N/A |
| 52 Week Low | $7.41 | $17.22 |
| 52 Week High | $15.09 | $25.93 |
Technical Indicators
Market Signals| Indicator | ECVT | LTGO |
|---|---|---|
| Relative Strength Index (RSI) | 48.34 | 56.70 |
| Support Level | $9.84 | $21.27 |
| Resistance Level | $10.61 | $25.17 |
| Average True Range (ATR) | 0.30 | 1.98 |
| MACD | 0.12 | -0.10 |
| Stochastic Oscillator | 58.20 | 42.88 |
Price Performance
Historical ComparisonAbout ECVT Ecovyst Inc.
Ecovyst Inc is an integrated and provider of materials, specialty catalysts and services. Its products contribute to lower emissions and cleaner air, higher fuel efficiency and cleaner fuels, and key enablers to advance transition to clean energy. The company has one operating segment. The Company's single reportable segment, Ecoservices, derives its revenue through the sale of virgin and regenerated sulfuric acid products and services.
About LTGO Latigo Biotherapeutics Inc. Common Stock
Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.